MYC and cancer: Next, we investigated how rare mutations might affect the 10 canonical cancer molecular pathways: cell cycle, Hippo, MYC, NOTCH, NRF2, PI-3-Kinase/AKT, RTK-RAS, TGFβ signaling, p53, and β-catenin/WNT.